MDXG Mimedx (MDXG) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001376339
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
128
13F, latest reported quarter
Mimedx insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for MIMEDX GROUP, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 17, 2025.
- The trade is 24.6% of the 236,982 shares held after it.
- No other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Maersk-Moller Kimberly sold about $432.6K of MDXG on Nov 6, 2025; 128 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 23, 2023.
- +20.8% median (+20.8% mean) 90-day return after 2 previous buys.
- The trade is 37.8% of the 529,530 shares held after it.
- No other insider bought within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Capper Joseph H bought about $1.3M of MDXG on May 2, 2025, the largest insider purchase at the company on our record; 128 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 13, 2025.
- The trade is 0.6% of the 309,077 shares held after it.
- 1 other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Maersk-Moller Kimberly sold about $14.1K of MDXG on Mar 17, 2025; 1 other insider sold within 30 days and 128 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 10, 2025.
- The trade is 7.4% of the 460,544 shares held after it.
- 2 other insiders sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and CAO Hulse William Frank IV sold about $270.1K of MDXG on Mar 13, 2025; 2 other insiders sold within 30 days and 128 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 10, 2025.
- The trade is 4.6% of the 440,178 shares held after it.
- 2 other insiders sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and CAO Hulse William Frank IV sold about $160.7K of MDXG on Mar 13, 2025; 2 other insiders sold within 30 days and 128 funds added in the latest 13F quarter.64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
128 funds bought in last quarter
more than 69% of Medical Devices
Revenue
+20.0% year over year
more than 72% of Medical Devices
Margin
11.6% net margin
more than 84% of Medical Devices
Buybacks
$12.5M repurchased, FY to 2026-06-30
below 58% of Medical Devices
Short interest
8.1% of the float short (float per yahoo 2026-10-27) · 9.1 days to cover · settled 2026-10-15
more than 74% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MDXG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.0%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MDXG: institutional holders (13F)
13F holdings, latest reported quarter
28,195,249 sh
$108.6M
12,154,466 sh
$46.8M
9,535,104 sh
$36.7M
7,173,770 sh
$27.6M
5,578,920 sh
$21.5M
Congress trades in MDXG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MDXG planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MDXG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Paradigm Micro-Cap Fund
$2.3M position · as of 2026-06-30
1.3%
iShares US Small Cap Value Factor ETF
$872.8K position · as of 2026-06-30
0.4%
Victory Integrity Discovery Fund
$297.6K position · as of 2026-06-30
0.3%
Invesco NASDAQ Future Gen 200 ETF
$57.8K position · as of 2026-05-31
0.3%
Schwab Small-Cap Equity Fund
$1.8M position · as of 2026-07-31
0.3%
ACUITAS US MICROCAP FUND
$315.7K position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
0 active
2
Not applicable
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Mimedx Group, Inc. Pac
Cycle 2026 · $0K spent
$0
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 128 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MDXG financials
Revenue growth
+20.0%
XBRL, annual
Net margin
11.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$355.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MDXG
| FY Dec 2025 | $418.6M |
| FY Dec 2024 | $348.9M |
| FY Dec 2023 | $321.5M |
| FY Dec 2022 | $267.8M |
| FY Dec 2021 | $258.6M |
| Jun 2026 | $64.4M |
| Mar 2026 | $59.0M |
| Dec 2025 | $118.1M |
| Sep 2025 | $113.7M |
| Jun 2025 | $98.6M |
| Mar 2025 | $88.2M |
| Dec 2024 | $92.9M |
| Sep 2024 | $84.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+1.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MDXG
| FY Dec 2025 | +11.6% |
| FY Dec 2024 | +12.2% |
| FY Dec 2023 | +18.1% |
| FY Dec 2022 | -11.3% |
| FY Dec 2021 | -4.0% |
| Jun 2026 | -23.1% |
| Mar 2026 | -18.4% |
| Dec 2025 | +12.9% |
| Sep 2025 | +14.7% |
| Jun 2025 | +9.8% |
| Mar 2025 | +8.0% |
| Dec 2024 | +8.0% |
| Sep 2024 | +9.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$44.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MDXG
| FY Dec 2025 | $73.0M |
| FY Dec 2024 | $64.5M |
| FY Dec 2023 | $24.8M |
| FY Dec 2022 | -$19.4M |
| FY Dec 2021 | -$5.2M |
| Jun 2026 | -$10.6M |
| Mar 2026 | $1.3M |
| Dec 2025 | $24.7M |
| Sep 2025 | $29.1M |
| Jun 2025 | $14.2M |
| Mar 2025 | $4.9M |
| Dec 2024 | $22.5M |
| Sep 2024 | $19.6M |
At each fiscal year end
Single quarter
Debt to equity
0.08x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity MDXG
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.10x |
| FY Dec 2023 | 0.34x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 586.91x |
| Jun 2026 | 0.08x |
| Mar 2026 | 0.07x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.09x |
| Mar 2025 | 0.09x |
| Dec 2024 | 0.10x |
| Sep 2024 | 0.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
2.68x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt MDXG
| FY Dec 2025 | 4.12x |
| FY Dec 2024 | 3.52x |
| FY Dec 2023 | 0.55x |
| FY Dec 2022 | -0.37x |
| FY Dec 2021 | -0.04x |
| Jun 2026 | 2.68x |
| Mar 2026 | 4.01x |
| Dec 2025 | 4.12x |
| Sep 2025 | 3.72x |
| Jun 2025 | 3.15x |
| Mar 2025 | 3.51x |
| Dec 2024 | 3.52x |
| Sep 2024 | 3.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+2.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MDXG
| FY Dec 2025 | +21.6% |
| FY Dec 2024 | +25.3% |
| FY Dec 2023 | +93.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +2.9% |
| Mar 2026 | +13.8% |
| Dec 2025 | +21.6% |
| Sep 2025 | +19.4% |
| Jun 2025 | +16.7% |
| Mar 2025 | +22.4% |
| Dec 2024 | +25.3% |
| Sep 2024 | +97.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MDXG
| FY Dec 2025 | +16.0% |
| FY Dec 2024 | +16.9% |
| FY Dec 2023 | +28.4% |
| FY Dec 2022 | -16.8% |
| FY Dec 2021 | -5.3% |
| Jun 2026 | +2.2% |
| Mar 2026 | +10.6% |
| Dec 2025 | +16.0% |
| Sep 2025 | +14.5% |
| Jun 2025 | +12.3% |
| Mar 2025 | +16.3% |
| Dec 2024 | +16.9% |
| Sep 2024 | +40.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+4.5%
operating income after a 45.9% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital MDXG
| FY Dec 2025 | +43.6% |
| FY Dec 2024 | +46.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +4.5% |
| Mar 2026 | +26.7% |
| Dec 2025 | +43.6% |
| Sep 2025 | +35.0% |
| Jun 2025 | +26.5% |
| Mar 2025 | +32.8% |
| Dec 2024 | +46.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+3.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MDXG
| FY Dec 2025 | +25.7% |
| FY Dec 2024 | +28.6% |
| FY Dec 2023 | +23.1% |
| FY Dec 2022 | -10.8% |
| FY Dec 2021 | -4.9% |
| Jun 2026 | +3.6% |
| Mar 2026 | +16.1% |
| Dec 2025 | +25.7% |
| Sep 2025 | +23.3% |
| Jun 2025 | +19.9% |
| Mar 2025 | +26.5% |
| Dec 2024 | +28.6% |
| Sep 2024 | +36.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
96.25x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing MDXG
| FY Dec 2025 | 21.16x |
| FY Dec 2024 | 34.36x |
| FY Dec 2023 | 23.08x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 96.25x |
| Mar 2026 | 19.75x |
| Dec 2025 | 21.16x |
| Sep 2025 | 25.85x |
| Jun 2025 | 29.10x |
| Mar 2025 | 28.15x |
| Dec 2024 | 34.36x |
| Sep 2024 | 9.85x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$442.5M
market value at close 2026-10-26 on 2026-07-23 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value MDXG
| FY Dec 2025 | $854.5M |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $987.7M |
| FY Dec 2022 | $298.6M |
| FY Dec 2021 | $638.4M |
| Jun 2026 | $454.8M |
| Mar 2026 | $444.7M |
| Dec 2025 | $854.5M |
| Sep 2025 | $908.9M |
| Jun 2025 | $802.1M |
| Mar 2025 | $1.0B |
| Dec 2024 | $1.3B |
| Sep 2024 | $797.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield MDXG
| FY Dec 2025 | +7.3% |
| FY Dec 2024 | +4.6% |
| FY Dec 2023 | +2.4% |
| FY Dec 2022 | -6.1% |
| FY Dec 2021 | -0.8% |
| Jun 2026 | +7.8% |
| Mar 2026 | +11.8% |
| Dec 2025 | +7.3% |
| Sep 2025 | +6.9% |
| Jun 2025 | +6.8% |
| Mar 2025 | +6.1% |
| Dec 2024 | +4.6% |
| Sep 2024 | +6.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -81%, PEG needs growth
PEG, trailing MDXG
| FY Dec 2025 | 1.48x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 1.48x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M |
| Gross profit | $345.6M | $288.8M | $266.8M | $219.5M |
| Operating income | $63.9M | $58.9M | $37.1M | -$14.7M |
| Net income | $48.6M | $42.4M | $58.2M | -$30.2M |
| EPS (diluted) | 0.32 | 0.28 | 0.37 | -0.33 |
| Operating cash flow | $74.0M | $66.2M | $26.8M | -$17.9M |
| Cash | $166.1M | $104.4M | $82.0M | $66.0M |
| Long-term debt | $16.5M | $17.8M | $48.1M | $48.6M |
| Buybacks | $0 | $0 | $9.5M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
MDXG Stock Sonar score 5/7 axes
Find similar shapesCompareMDXG ranks highest on financial health (83rd percentile) and growth (72nd), and lowest on profitability (58th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
